Elotuzumab

Information about Elotuzumab

Elotuzumab is a humanized monoclonal antibody to cell surface receptor SLAMF7 which is used in combination with other antineoplastic agents in the therapy of multiple myeloma. 

Liver safety of Elotuzumab

Elotuzumab has been implicated in rare instances of transient, marked serum enzyme elevations, but has not been linked to instances of clinically apparent liver injury with jaundice.  

Mechanism of action of Elotuzumab

Elotuzumab (el" oh tooz' ue mab) is humanized IgG1 monoclonal antibody to the cell surface receptor signaling lymphocyte activation molecule family member 7 (SLAMF7), which is a transmembrane glycoprotein that is frequently overexpressed on multiple myeloma cells and is found normally on natural killer (NK) cells.  The monoclonal antibody binds to the cell surface receptor and triggers cell apoptosis of cancer cells and activation of NK cells which may increase its antineoplastic activity.  In preregistration trials, the addition of elotuzumab to lenalidomide and dexamethasone led to an increase in overall response rates and prolongation of progression-free survival. 

FDA approval information for Elotuzumab

Elotuzumab was given accelerated approval for use in the United States in 2015.  Current indications are as therapy of refractory multiple myeloma administered in combination with lenalidomide (or bortezomib) and dexamethasone or as monotherapy in patients who have failed at least three previous regimens.  Elotuzumab is available as a powder for reconstitution in single use vials of 300 or 400 mg under the brand name Empliciti. 

Dosage and administration for Elotuzumab

The recommended dose is 10 mg/kg intravenously every week for 2 cycles and every 2 weeks thereafter until disease progression or unacceptable toxicities occur. 

Side effects of Elotuzumab

Premedication with dexamethasone, diphenhydramine, ranitidine and acetaminophen is recommended.  side effects are common and can include infusion reactions, fatigue, diarrhea, constipation, anorexia, fever, cough, nasopharyngitis, peripheral neuropathy and pneumonia.  Uncommon, but potentially severe adverse reactions include severe infusion reactions, bacterial infections and secondary malignancies.

 

The article on Elotuzumab is a stub. YOU can help Wikimd by expanding it!

Medication resources

WikiMD is a sponsored by W8MD Weight loss, sleep and medical aesthetics.

Learn more

• Dailymed label info
• Scientific articles

edit 

About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Elotuzumab or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.